<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432029</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-180506</org_study_id>
    <nct_id>NCT00432029</nct_id>
  </id_info>
  <brief_title>Correlation of Flicker Induced and Flow Mediated Vasodilatation in Patients With Endothelial Dysfunction and Healthy Volunteers.</brief_title>
  <official_title>Correlation of Flicker Induced and Flow Mediated Vasodilatation in Patients With Endothelial Dysfunction and Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      A couple of studies have shown that illuminating the eye with diffuse flickering light is&#xD;
      accompanied by an increase of retinal vessel diameters, optic nerve head blood flow and&#xD;
      retinal blood flow. We have recently used this visual stimulation technique as a new and&#xD;
      powerful tool for the non-invasive investigation of vascular reactivity. Additionally, we&#xD;
      could show that this response is diminished in patients with vascular pathologies and that&#xD;
      the response is dependent on nitric oxide, indicating that flicker induced vasodilatation may&#xD;
      reflect endothelial dysfunction and may be a new approach to test endothelial function in&#xD;
      vivo.&#xD;
&#xD;
      One of the most widely used method for the assessment of endothelial function is flow&#xD;
      mediated dilatation (FMD). FMD has been shown to give a reliable estimate of vascular&#xD;
      function in vivo. In the present study, we set out to compare the standard method for the&#xD;
      evaluation of endothelial function, FMD, to flicker induced vasodilatation in the retina.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal vessel diameters (Retinal vessel analyzer)</measure>
    <time_frame>8 min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Forearm Blood Flow</measure>
    <time_frame>8 min</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Hypertension</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Regional Blood Flow</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>IDDM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hypercholesterolemia and/or Hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>age/sex matched healthy control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Forearm blood flow measurement, Flow mediated dilation (FMD)</intervention_name>
    <description>Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light</intervention_name>
    <description>Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with diabetic retinopathy:&#xD;
&#xD;
          -  Men and women aged &gt; 18 years.&#xD;
&#xD;
          -  Normal findings in the medical history unless the investigator considers an&#xD;
             abnormality to be clinically irrelevant.&#xD;
&#xD;
          -  Inclusion criteria of patients are insulin dependent diabetes mellitus (IDDM) with non&#xD;
             or mild non-proliferative diabetic retinopathy. Patients with no signs of diabetic&#xD;
             retinopathy (level 1) or patients with one or more microaneurysms (level 2) will be&#xD;
             included. Level of diabetic retinopathy will be assessed according to the criteria&#xD;
             defined in the AREDS-study.(1991)&#xD;
&#xD;
          -  serum cholesterol &lt; 250 mg/dl (treated or untreated)&#xD;
&#xD;
        Patients with mild hypertension and/or hypercholesterinemia:&#xD;
&#xD;
          -  Men and women aged &gt; 18 years.&#xD;
&#xD;
          -  mild essential hypertension defined as a blood pressure meeting the criterion of&#xD;
             hypertension grade 1 of the World Health Organisation blood pressure classification&#xD;
&#xD;
          -  systolic blood pressure between 140 and 159 mmHg and diastolic blood pressure between&#xD;
             90 and 99 mmHg and/or&#xD;
&#xD;
          -  serum cholesterol &gt; 250 mg/dl&#xD;
&#xD;
          -  blood pressure will be measured at two different occasion in a sitting positions&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
          -  Men and women aged &gt; 18 years.&#xD;
&#xD;
          -  Normal findings in the medical history unless the investigator considers an&#xD;
             abnormality to be clinically irrelevant&#xD;
&#xD;
          -  normal ocular findings&#xD;
&#xD;
          -  serum cholesterol &lt; 200 mg/dl&#xD;
&#xD;
          -  systolic blood pressure between 110mmHg and 140mmHg&#xD;
&#xD;
          -  diastolic blood pressure &lt; 90 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks&#xD;
             preceding the study&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day&#xD;
&#xD;
          -  Blood donation during the previous 3 weeks&#xD;
&#xD;
          -  other ocular pathologies than diabetic retinopathy level 1 or 2&#xD;
&#xD;
          -  History or family history of epilepsy&#xD;
&#xD;
          -  Ametropy greater or equal than 3 dpt&#xD;
&#xD;
          -  systolic blood pressure &lt; 100mmHg&#xD;
&#xD;
          -  diastolic blood pressure &lt; 75mmHg&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wolzt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>February 5, 2007</study_first_submitted>
  <study_first_submitted_qc>February 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2007</study_first_posted>
  <last_update_submitted>July 1, 2008</last_update_submitted>
  <last_update_submitted_qc>July 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Michael Wolzt</name_title>
    <organization>Medical University of Vienna Department of Clinical Pharmacology</organization>
  </responsible_party>
  <keyword>Flicker induced vasodilatation</keyword>
  <keyword>Flow mediated vasodilatation</keyword>
  <keyword>Forearm blood flow</keyword>
  <keyword>Retinal vessel diameter</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

